Related Experiment Video
Updated: Dec 19, 2025

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
GRK5 Controls SAP97-Dependent Cardiotoxic β1 Adrenergic Receptor-CaMKII Signaling in Heart Failure
Bing Xu1,2, Minghui Li2,3, Ying Wang2
1From the VA Northern California Health Care System, Mather, CA (B.X., Y.K.X.).
Insights
The scaffold protein SAP97 is crucial for maintaining cardiac β1AR signaling integrity. Its loss exacerbates heart failure by promoting detrimental CaMKII signaling pathways.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Signal Transduction
Background:
- Cardiotoxic β1 adrenergic receptor (β1AR) signaling, involving CaMKII, is critical in heart failure development.
- SAP97 (synapse-associated protein 97) is a scaffold protein that organizes the β1AR signalosome.
Purpose of the Study:
- To elucidate the dynamics of the β1AR-SAP97 signalosome.
- To investigate the role of this complex in chronic cardiotoxic signaling contributing to heart failure.
Main Methods:
- Examined the integrity of the cardiac β1AR-SAP97 complex in heart failure models.
- Generated cardiac-specific SAP97 deletion in mice to study β1AR signaling.
- Investigated effects of aging, adrenergic stimulation, and pressure overload.
Main Results:
- Reduced β1AR-SAP97 complex integrity in heart failure.
- Cardiac SAP97 deletion caused cardiomyopathy and exacerbated cardiac dysfunction.
- Loss of SAP97 promoted PKA- and Epac-dependent CaMKII activation, driving detrimental remodeling.
- GRK5 (G-protein receptor kinase-5) mediates SAP97 dissociation from β1AR.
Conclusions:
- SAP97 is critical for maintaining cardiac β1AR signaling integrity.
- A detrimental cardiac GRK5-CaMKII axis contributes to heart failure.
- This axis presents a potential therapeutic target for heart failure.
Rationale:
Cardiotoxic β1 adrenergic receptor (β1AR)-CaMKII (calmodulin-dependent kinase II) signaling is a major and critical feature associated with development of heart failure. SAP97 (synapse-associated protein 97) is a multifunctional scaffold protein that binds directly to the C-terminus of β1AR and organizes a receptor signalosome.
Objective:
We aim to elucidate the dynamics of β1AR-SAP97 signalosome and its potential role in chronic cardiotoxic β1AR-CaMKII signaling that contributes to development of heart failure.
Methods And Results:
The integrity of cardiac β1AR-SAP97 complex was examined in heart failure. Cardiac-specific deletion of SAP97 was developed to examine β1AR signaling in aging mice, after chronic adrenergic stimulation, and in pressure overload hypertrophic heart failure. We show that the β1AR-SAP97 signaling complex is reduced in heart failure. Cardiac-specific deletion of SAP97 yields an aging-dependent cardiomyopathy and exacerbates cardiac dysfunction induced by chronic adrenergic stimulation and pressure overload, which are associated with elevated CaMKII activity. Loss of SAP97 promotes PKA (protein kinase A)-dependent association of β1AR with arrestin2 and CaMKII and turns on an Epac (exchange protein directly activated by cAMP)-dependent activation of CaMKII, which drives detrimental functional and structural remodeling in myocardium. Moreover, we have identified that GRK5 (G-protein receptor kinase-5) is necessary to promote agonist-induced dissociation of SAP97 from β1AR. Cardiac deletion of GRK5 prevents adrenergic-induced dissociation of β1AR-SAP97 complex and increases in CaMKII activity in hearts.
Conclusions:
These data reveal a critical role of SAP97 in maintaining the integrity of cardiac β1AR signaling and a detrimental cardiac GRK5-CaMKII axis that can be potentially targeted in heart failure therapy. Graphical Abstract: A graphical abstract is available for this article.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
G-Protein Gated Ion Channels
Sensory...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inotropic Agents
Heart Failure II: Pathophysiology

